TTNP Archives | BioTuesdays

Developments

Titan Pharma’s Probuphine added to Federal Supply Schedule

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, a novel six-month maintenance treatment for opioid use disorder (OUD), will be included on the Federal Supply Schedule (FSS) beginning on January 15, 2020. The...

January 13, 2020

Developments

Kate DeVarney joins Titan Pharma’s Board

Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting. Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January...

December 30, 2019

Markets

Maxim ups Titan Pharma to buy with PT of $1

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold,” establishing a $1 price target as the company has raised capital and removed a financing overhang. The stock was quoted at 20 cents in...

October 23, 2019

Developments

Titan Pharma to present two Probuphine posters at conference

Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics. Probuphine is a subdermal implant that provides six-month...

October 22, 2019

Developments

Titan Pharma gets second year of NIDA funding for nalmefene implant development

The National Institutes of Health’s National Institute on Drug Abuse (NIDA) approved $6.1-million in second-year funding for Titan Pharmaceuticals‘ (NASDAQ:TTNP) development of a nalmefene implant. Titan is using...

September 18, 2019

Developments

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

Knight Therapeutics (TSX:GUD) reached agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a letter of intent covering reimbursement of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first...

August 6, 2019

Features

Titan Pharma relaunch of Probuphine paying early dividends

Titan Pharmaceuticals’ (NASDAQ:TTNP) relaunch of its Probuphine implant for the long-term maintenance treatment of opioid use disorder (OUD) demonstrated promising results with a meaningful increase in product shipments...

January 15, 2019

Executive Moves

Titan Pharma hires commercialization veteran, Dane Hallberg

Titan Pharmaceuticals (NASDAQ:TTNP) appointed Dane Hallberg to the newly created position of EVP and chief commercial officer, effective immediately, with responsibility for leading all of the company’s commercial...

October 2, 2018

Developments

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of...

April 20, 2018

Developments

Molteni acquires Titan Pharma’s European Probuphine IP

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a definitive asset purchase, supply and support agreement with closely-held L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, through which...

March 22, 2018

Tag - TTNP

Titan Pharma’s Probuphine added to Federal Supply Schedule

Kate DeVarney joins Titan Pharma’s Board

Maxim ups Titan Pharma to buy with PT of $1

Titan Pharma to present two Probuphine posters at conference

Titan Pharma gets second year of NIDA funding for nalmefene implant development

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

Titan Pharma relaunch of Probuphine paying early dividends

Titan Pharma hires commercialization veteran, Dane Hallberg

Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada

Molteni acquires Titan Pharma’s European Probuphine IP

Follow Us

General

More

Subscribe